Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Cyst Fibros ; 20(3): 540-550, 2021 05.
Article in English | MEDLINE | ID: mdl-33309058

ABSTRACT

BACKGROUND: Approximately 10% of people with cystic fibrosis (CF) have mutations that result in little to no CFTR production and thus cannot benefit from CFTR modulators. We previously found that Amphotericin B (AmB), a small molecule that forms anion channels, restored HCO3- secretion and increased host defenses in primary cultures of CF airway epithelia. Further, AmB increased ASL pH in CFTR-null pigs, suggesting an alternative CFTR-independent approach to achieve gain-of-function. However, it remains unclear whether this approach can be effective in people. METHODS: To determine whether AmB can impact physiology in people with CF, we first tested whether Fungizone, a clinically approved AmB formulation, could cause electrophysiological effects consistent with anion secretion in primary cultures of CF airway epithelia. We then evaluated the capacity of AmB to change nasal potential difference (NPD), a key clinical biomarker, in people with CF not on CFTR modulators. RESULTS: AmB increased transepithelial Cl- current and hyperpolarized calculated transepithelial voltage in primary cultures of CF airway epithelia from people with two nonsense mutations. In eight people with CF not on CFTR modulators, intranasal Fungizone treatment caused a statistically significant change in NPD. This change was similar in direction and magnitude to the effect of ivacaftor in people with a G551D mutation. CONCLUSIONS: Our results provide the first evidence that AmB can impact a clinical biomarker in people with CF. These results encourage additional clinical studies in people with CF to determine whether small molecule anion channels can provide benefit.


Subject(s)
Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Cystic Fibrosis Transmembrane Conductance Regulator/drug effects , Cystic Fibrosis/drug therapy , Voltage-Dependent Anion Channels/drug effects , Administration, Intranasal , Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Cells, Cultured , Codon, Nonsense , Cystic Fibrosis/genetics , Humans , Respiratory Mucosa/cytology
2.
Nature ; 567(7748): 405-408, 2019 03.
Article in English | MEDLINE | ID: mdl-30867598

ABSTRACT

Loss-of-function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) compromise epithelial HCO3- and Cl- secretion, reduce airway surface liquid pH, and impair respiratory host defences in people with cystic fibrosis1-3. Here we report that apical addition of amphotericin B, a small molecule that forms unselective ion channels, restored HCO3- secretion and increased airway surface liquid pH in cultured airway epithelia from people with cystic fibrosis. These effects required the basolateral Na+, K+-ATPase, indicating that apical amphotericin B channels functionally interfaced with this driver of anion secretion. Amphotericin B also restored airway surface liquid pH, viscosity, and antibacterial activity in primary cultures of airway epithelia from people with cystic fibrosis caused by different mutations, including ones that do not yield CFTR, and increased airway surface liquid pH in CFTR-null pigs in vivo. Thus, unselective small-molecule ion channels can restore host defences in cystic fibrosis airway epithelia via a mechanism that is independent of CFTR and is therefore independent of genotype.


Subject(s)
Cystic Fibrosis/metabolism , Epithelium/metabolism , Ion Channels/metabolism , Respiratory Mucosa/metabolism , Respiratory System/metabolism , Amphotericin B/pharmacology , Animals , Bicarbonates/metabolism , Cells, Cultured , Cystic Fibrosis/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/deficiency , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Epithelial Cells/cytology , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelium/drug effects , Female , Humans , Hydrogen-Ion Concentration , Male , Respiratory Mucosa/drug effects , Respiratory System/drug effects , Sodium-Potassium-Exchanging ATPase/metabolism , Swine
3.
BMC Nephrol ; 16: 105, 2015 Jul 14.
Article in English | MEDLINE | ID: mdl-26169052

ABSTRACT

BACKGROUND: Recent studies suggest discrepancies between patients and providers around perceptions of hemodialysis prognosis. Such data are lacking for continuous renal replacement therapy (CRRT). We aim to assess patient and provider understanding of outcomes around CRRT. METHODS: From February 1 to August 31, 2013, a triad of (1) a patient on CRRT (or health care proxy [HCP]), (2) physician and (3) primary nurse from the intensive care unit (ICU) team were surveyed. Univariate chi-square and qualitative analysis techniques were used. RESULTS: Ninety-six total participants (32 survey triads) were completed. Ninety one percent of patients/HCPs correctly identified that CRRT replaced the function of the kidneys. Six percent of patients/HCPs, 44 % of physicians, and 44 % of nurses identified rates of survival to hospital discharge that were consistent with published literature. Both physicians and nurses were more likely than patients/HCPs to assess survival consistently with published data (p = 0.001). Patients/HCPs were more likely to overestimate survival rates than physicians and nurses (p < 0.001). Thirty eight percent of patients/HCPs, 38 % of physicians, and 28 % of nurses identified rates of lifelong dialysis-dependence among surviving patients that were consistent with published literature. CONCLUSIONS: There is mismatch between patients, HCPs, and providers around prognosis of CRRT. Patients/HCPs are more likely to overestimate chances of survival than physicians or nurses. Further intervention is needed to improve this knowledge gap.


Subject(s)
Acute Kidney Injury/therapy , Clinical Competence , Health Knowledge, Attitudes, Practice , Kidney Failure, Chronic/therapy , Nurses , Physicians , Renal Dialysis/methods , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Intensive Care Units , Male , Middle Aged , Prognosis , Proxy , Renal Replacement Therapy/methods
4.
Org Lett ; 15(22): 5698-701, 2013 Nov 15.
Article in English | MEDLINE | ID: mdl-24161124

ABSTRACT

A flow chemistry process for the Oppenauer oxidation of benzylic secondary alcohols using partially hydrated zirconium oxide and a simple carbonyl containing oxidant such as acetone, cyclohexanone, and neopentanal is reported. The heterogeneous oxidative system could be applied to a wide range of functionalized alcohol substrates, allowing clean and fast delivery of ketone products within a few minutes between 40 and 100 °C.


Subject(s)
Benzyl Alcohols/chemistry , Benzyl Alcohols/chemical synthesis , Zirconium/chemistry , Catalysis , Molecular Structure , Oxidation-Reduction
SELECTION OF CITATIONS
SEARCH DETAIL
...